Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-10-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第三届监事会第二十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the third Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It includes details about the meeting's convening, attendance, and the approval of the 2023 third quarter report and adjustments to related party transaction limits. The document does not contain the full quarterly report itself but rather the Supervisory Board's approval and confirmation that the report was prepared in compliance with regulations. It also references that the full 2023 third quarter report is disclosed on an external website. The document length is short (1449 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement related to corporate governance and compliance but does not contain substantive financial data or the full report.
2023-10-27 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的事前认可意见
Board/Management Information Classification · 90% confidence The document is a statement from independent directors providing their prior approval opinion on a specific board meeting agenda item related to adjustments and increases in the estimated amount of daily related-party transactions for the year 2023. It references regulatory frameworks and company bylaws but does not contain financial statements or detailed financial data. The document is a governance-related opinion or approval rather than a full report or announcement of financial results. It is not a full Annual Report, Interim Report, or Audit Report. It is also not a simple announcement or certification but a formal governance-related document related to board matters. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements related to board or senior management matters, including approvals and opinions from directors.
2023-10-27 Chinese
关于2023年度日常关联交易调整暨增加预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding adjustments and increases in the estimated amount of daily related-party transactions for the year 2023. It details the nature of these related-party transactions, the parties involved, pricing policies, approvals by the board and supervisory committee, independent directors' opinions, and the review by the sponsor institution. The document is regulatory in nature, disclosing related-party transaction adjustments and approvals, but it does not contain financial statements or comprehensive financial performance data. It is not an annual or interim report, earnings release, or management discussion. It is a formal regulatory announcement about related-party transactions, which fits best under Regulatory Filings (RNS). The document length is over 11,000 characters, so it is not a brief report publication announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-10-27 Chinese
第三届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 21st meeting of the third board of directors of Shenzhen BGI Genomics Co., Ltd. It includes details about the meeting date, attendance, and voting results on specific agenda items such as the approval of the 2023 third quarter report and adjustments to related party transaction limits. The document does not contain the full financial report itself but references that the 2023 third quarter report was disclosed on the same day on an external website. The document is relatively short (1419 characters) and serves as a formal announcement of board decisions rather than the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-10-27 Chinese
独立董事关于第三届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a board meeting agenda item about adjustments to related party transactions for the fiscal year 2023. It references compliance with regulatory guidelines and company bylaws, and it is a formal statement of opinion rather than a financial report or announcement of voting results. The content focuses on board-level governance and approval of related party transactions, which aligns with Board/Management Information filings. The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a voting result announcement since it is an opinion statement, not the official vote tally. Therefore, the best classification is Board/Management Information (MANG).
2023-10-27 Chinese
关于全资子公司人乳头瘤病毒（HPV）分型检测产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary obtaining a medical device registration certificate for an HPV genotyping detection product. The content focuses on product certification, market context, and potential impact on the company. There is no financial data, no mention of financial results, no regulatory filings related to financial statements, no voting results, no management changes, no merger or acquisition activity, and no report publication. The document is an official announcement about a regulatory approval related to a product, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-10-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.